About Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio-11.3600583090379
Forward P/E Ratio-10.68
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$10.14 per share
Price / Book7.69
Return on Equity-74.10%
Return on Assets-65.98%
Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions
What is Esperion Therapeutics' stock symbol?
Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."
How were Esperion Therapeutics' earnings last quarter?
Esperion Therapeutics Inc (NASDAQ:ESPR) announced its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Zacks' consensus estimate of ($1.79) by $0.07. During the same quarter in the prior year, the company posted ($0.77) earnings per share. View Esperion Therapeutics' Earnings History.
When will Esperion Therapeutics make its next earnings announcement?
Where is Esperion Therapeutics' stock going? Where will Esperion Therapeutics' stock price be in 2018?
12 Wall Street analysts have issued 1 year price targets for Esperion Therapeutics' shares. Their predictions range from $45.00 to $105.00. On average, they expect Esperion Therapeutics' share price to reach $76.33 in the next year. View Analyst Ratings for Esperion Therapeutics.
What are Wall Street analysts saying about Esperion Therapeutics stock?
Here are some recent quotes from research analysts about Esperion Therapeutics stock:
- 1. Chardan Capital analysts commented, "We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe (BA+eze) fixed dose combo (FDC) has been confirmed by the FDA. A definition of statin intolerance has also been agreed on by the FDA. KOLs (e.g. Dr. Nissen) support the need for therapies for patients who are (or believe themselves to be) statin intolerant and refuse statins. CANTOS suggests BA’s high-sensitivity C-reactive protein (hsCRP) lowering effect is highly relevant for CV event reduction and outcomes. Newly-disclosed integrated phase II results suggest sound BA safety. A larger market opportunity results from a pivotal BA phase III design that includes patients “on any statin dose.” Limited use of PCSK9 inhibitors, due to pricing, opens an opportunity. Merck’s (unrated) decision not to file anacetrapib for approval further confirms oral CETP inhibitors as uninteresting assets or competitors." (12/5/2017)
- 2. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (8/23/2017)
- 3. Needham & Company LLC analysts commented, "The FDA has agreed that the Phase III CLEAR LDL program of bempedoic acid is sufficient to support approval. This resolves a long standing issue for ESPR shares regarding the ability to get their drug approved without a completed CVOT. This regulatory confirmation comes on the heals of the positive FOURIER outcomes data for Repatha and the genetic validation of the target for bempedoic acid which was presented yesterday at the American College for Cardiology (ACC). As a result of this trifecta of positive news we are increasing our price target on ESPR to $58 from $25. We once again model US approval based on CLEAR LDL in 2020." (3/20/2017)
Who are some of Esperion Therapeutics' key competitors?
Some companies that are related to Esperion Therapeutics include Blueprint Medicines (BPMC), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI), Ligand Pharmaceuticals (LGND), Shire Viropharma (VPHM), Portola Pharmaceuticals (PTLA), Immunomedics (IMMU), Foundation Medicine (FMI), Global Blood Therapeutics (GBT), Ironwood Pharmaceuticals (IRWD), Spectrum Pharmaceuticals (SPPI), Intrexon (XON), Crispr Therapeutics (CRSP), Genus (GNS), Editas Medicine (EDIT), Heron Therapeutics (HRTX), Medpace (MEDP) and Arena Pharmaceuticals (ARNA).
Who are Esperion Therapeutics' key executives?
Esperion Therapeutics' management team includes the folowing people:
- Timothy M. Mayleben, President, Chief Executive Officer, Director (Age 56)
- Richard B. Bartram, Chief Financial Officer and Principal Financial Officer (Age 36)
- Narendra D. Lalwani Ph.D., FAHA, DABT, Chief Operating Officer, Executive Vice President - Research & Development (Age 64)
- Nicole Vitullo MBA, Independent Lead Director (Age 59)
- Jeffrey Berkowitz J.D., Director (Age 51)
- Roger S. Newton Ph.D., FAHA, FACN, Director (Age 66)
- Scott N. Braunstein M.D., Independent Director (Age 53)
- Dov A. Goldstein M.D., Independent Director (Age 49)
Who owns Esperion Therapeutics stock?
Esperion Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Meditor Group Ltd (8.87%),
ALTA PARTNERS VIII, L.P.
ALTA PARTNERS VIII, L.P.
(2.70%), Wasatch Advisors Inc. (2.65%), Hamilton Lane Advisors LLC (0.44%) and Schwab Charles Investment Management Inc. (0.35%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani, Nicole Vitullo and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.
Who sold Esperion Therapeutics stock? Who is selling Esperion Therapeutics stock?
Esperion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc. and Schwab Charles Investment Management Inc.. Company insiders that have sold Esperion Therapeutics company stock in the last year include Dov A Md Goldstein and Nicole Vitullo. View Insider Buying and Selling for Esperion Therapeutics.
Who bought Esperion Therapeutics stock? Who is buying Esperion Therapeutics stock?
Esperion Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Hamilton Lane Advisors LLC, Meditor Group Ltd, Bank of Montreal Can, Oakmont Partners LLC and Creative Planning. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics.
How do I buy Esperion Therapeutics stock?
Shares of Esperion Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Esperion Therapeutics' stock price today?
One share of Esperion Therapeutics stock can currently be purchased for approximately $77.93.
How big of a company is Esperion Therapeutics?
Esperion Therapeutics has a market capitalization of $2 billion. The biopharmaceutical company earns $-74,970,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Esperion Therapeutics employs 44 workers across the globe.
How can I contact Esperion Therapeutics?
Esperion Therapeutics' mailing address is 3891 Ranchero Dr Ste 150, ANN ARBOR, MI 48108-2837, United States. The biopharmaceutical company can be reached via phone at +1-734-8873903 or via email at [email protected]
MarketBeat Community Rating for Esperion Therapeutics (ESPR)MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Esperion Therapeutics (NASDAQ:ESPR) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.75||2.67||2.67||2.55|
|Ratings Breakdown: ||0 Sell Rating(s)|
4 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$76.33||$61.17||$59.09||$40.95|
|Price Target Upside: ||1.12% downside||7.07% upside||9.35% upside||11.80% downside|
Esperion Therapeutics (NASDAQ:ESPR) Consensus Price Target History
Esperion Therapeutics (NASDAQ:ESPR) Analyst Ratings History
(Data available from 1/23/2016 forward)
Esperion Therapeutics (NASDAQ:ESPR) Earnings History and Estimates Chart
Esperion Therapeutics (NASDAQ ESPR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Esperion Therapeutics (NASDAQ:ESPR) Earnings Estimates
2018 EPS Consensus Estimate: ($8.54)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Esperion Therapeutics (NASDAQ:ESPR)
No dividend announcements for this company have been tracked by MarketBeat.com
Esperion Therapeutics (NASDAQ ESPR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 32.50%
Institutional Ownership Percentage: 92.30%
Esperion Therapeutics (NASDAQ ESPR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/6/2017||Nicole Vitullo||Director||Sell||9,326||$53.85||$502,205.10||2,472|| |
|3/22/2017||Dov A Md Goldstein||Director||Sell||800,000||$41.66||$33,328,000.00|| |
|3/21/2017||Gilbert S Omenn||Director||Buy||1,000||$42.26||$42,260.00||10,000|| |
|11/1/2016||Narendra D Lalwani||COO||Buy||5,000||$9.93||$49,650.00||5,000|| |
|7/6/2016||Mark E Mcgovern||Director||Buy||5,000||$10.00||$50,000.00||600|| |
|5/4/2016||Timothy M Mayleben||CEO||Buy||7,000||$14.85||$103,950.00||41,614|| |
|3/1/2016||Gilbert S Omenn||Director||Buy||5,000||$15.28||$76,400.00||10,000|| |
|1/27/2016||Timothy M Mayleben||CEO||Buy||3,600||$15.88||$57,168.00||34,614|| |
|1/15/2016||Timothy M Mayleben||CEO||Buy||7,200||$14.08||$101,376.00||31,014|| |
|4/24/2015||Dov A Md Goldstein||Director||Sell||217,469||$108.22||$23,534,495.18|| |
|11/18/2014||Patrick G Enright||Director||Sell||487,130||$32.78||$15,968,121.40|| |
|10/21/2014||Parters Vii L P Domain||Major Shareholder||Buy||500,000||$20.00||$10,000,000.00|| |
|10/7/2014||Longitude Capital Partners, Ll||Major Shareholder||Sell||11,927||$30.04||$358,287.08|| |
|7/1/2013||Brian H Dovey||Major Shareholder||Buy||285,714||$14.00||$3,999,996.00|| |
|7/1/2013||Daniel Janney||Director||Buy||235,714||$14.00||$3,299,996.00|| |
|7/1/2013||Roger S Newton||Chairman||Buy||42,346||$14.00||$592,844.00|| |
|7/1/2013||Timothy M Mayleben||CEO||Buy||5,000||$14.00||$70,000.00|| |
Esperion Therapeutics (NASDAQ ESPR) News Headlines
|Citi Downgrades Esperion As Hope Of Acquisition Dwindles|
www.benzinga.com - January 22 at 11:33 AM
| Analysts Anticipate Esperion Therapeutics Inc (ESPR) to Post -$1.80 Earnings Per Share|
www.americanbankingnews.com - January 20 at 5:22 AM
|Esperion Therapeutics (ESPR) Receives New Coverage from Analysts at Credit Suisse Group|
www.americanbankingnews.com - January 17 at 5:24 PM
|Esperion Therapeutics Target of Unusually High Options Trading (ESPR)|
www.americanbankingnews.com - January 15 at 4:40 AM
|Esperion Therapeutics (ESPR) Upgraded to Strong-Buy at BidaskClub|
www.americanbankingnews.com - January 13 at 4:52 PM
|Notable Friday Option Activity: BLK, ESPR, CZR - Nasdaq|
www.nasdaq.com - January 12 at 5:01 PM
|The 10 Best Stocks of 2017|
finance.yahoo.com - January 8 at 9:44 AM
|Esperion Therapeutics (ESPR) Upgraded to "Buy" by Bank of America|
www.americanbankingnews.com - January 6 at 10:28 PM
|Why Esperion Therapeutics Shares Skyrocketed 425.9% in 2017|
finance.yahoo.com - January 6 at 5:07 PM
|Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference|
finance.yahoo.com - January 3 at 5:13 PM
|Esperion Therapeutics Inc (ESPR) Given Average Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - January 2 at 3:40 PM
|Analyzing Esperion Therapeutics (ESPR) and GenVec (GNVC)|
www.americanbankingnews.com - January 2 at 7:30 AM
|30 Big Biotech Events Coming in 2018|
www.msn.com - December 30 at 9:29 AM
|Commit To Purchase Esperion Therapeutics At $28, Earn 20.4% Using Options|
www.nasdaq.com - December 22 at 9:47 AM
|-$1.80 EPS Expected for Esperion Therapeutics, Inc. (ESPR) This Quarter|
www.americanbankingnews.com - December 17 at 5:32 PM
|Esperion Therapeutics (ESPR) Upgraded at BidaskClub|
www.americanbankingnews.com - December 16 at 10:16 AM
|Esperion Therapeutics (ESPR) Appoints Jeffrey Berkowitz to Board - StreetInsider.com|
www.streetinsider.com - December 15 at 5:45 PM
|Esperion Therapeutics (ESPR) Upgraded to Strong-Buy by Needham & Company LLC|
www.americanbankingnews.com - December 14 at 8:32 PM
|Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors|
finance.yahoo.com - December 14 at 5:43 PM
|Needham & Company Upgrades Esperion Therapeutics (ESPR) to Strong Buy, Top Pick - StreetInsider.com|
www.streetinsider.com - December 14 at 9:47 AM
|Head to Head Review: Esperion Therapeutics (ESPR) and Intellia Therapeutics (NTLA)|
www.americanbankingnews.com - December 12 at 7:34 PM
|Esperion Therapeutics (ESPR) Rating Lowered to Hold at BidaskClub|
www.americanbankingnews.com - December 9 at 6:32 PM
|Esperion Therapeutics, Inc. (ESPR) Director Sells $502,205.10 in Stock|
www.americanbankingnews.com - December 8 at 5:50 PM
|Esperion Therapeutics, Inc. (ESPR) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - December 8 at 5:42 PM
|Chardan Capital Increases Esperion Therapeutics (ESPR) Price Target to $75.00|
www.americanbankingnews.com - December 6 at 10:38 PM
|Esperion Therapeutics' (ESPR) Hold Rating Reiterated at Chardan Capital|
www.americanbankingnews.com - December 5 at 8:48 PM
|3 Stocks That Quadrupled|
finance.yahoo.com - December 4 at 9:37 AM
|Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)|
globenewswire.com - December 1 at 4:59 PM
|Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)|
finance.yahoo.com - December 1 at 4:59 PM
|Esperion Therapeutics, Inc. Fundamental Analysis : November 30, 2017|
finance.yahoo.com - November 30 at 5:08 PM
|Zacks: Brokerages Anticipate Esperion Therapeutics, Inc. (ESPR) to Post -$1.80 Earnings Per Share|
www.americanbankingnews.com - November 29 at 3:18 PM
|Your Daily Pharma Scoop: Regeneron's Appeal, Good News For Amgen, Bristol-Myers' Sprycel|
seekingalpha.com - November 13 at 6:56 PM
|Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference|
finance.yahoo.com - November 13 at 6:56 PM
|Esperion Therapeutics, Inc. (ESPR) Given Consensus Rating of "Buy" by Brokerages|
www.americanbankingnews.com - November 13 at 3:59 PM
|Earnings Review and Free Research Report: Vertex’s Revenue Soared 40%; Adjusted EPS Rocketed 212%|
finance.yahoo.com - November 13 at 11:06 AM
|Esperion Therapeutics, Inc. (ESPR) Earns Buy Rating from Northland Securities|
www.americanbankingnews.com - November 10 at 11:20 PM
|Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference|
finance.yahoo.com - November 10 at 1:50 PM
|Equities Analysts Set Expectations for Esperion Therapeutics, Inc.'s FY2017 Earnings (ESPR)|
www.americanbankingnews.com - November 9 at 7:54 AM
|Esperion Therapeutics, Inc. (ESPR) Announces Quarterly Earnings Results|
www.americanbankingnews.com - November 8 at 4:44 PM
|Esperion Therapeutics, Inc. (ESPR) Expected to Post Q1 2018 Earnings of ($1.95) Per Share|
www.americanbankingnews.com - November 8 at 4:40 PM
|Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - November 8 at 6:37 AM
|Esperion Therapeutics (ESPR) Commences Pivotal Phase 3 Study ... - StreetInsider.com|
www.streetinsider.com - November 7 at 12:59 AM
|Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill|
finance.yahoo.com - November 6 at 7:57 PM
|Biotech Stocks on Investors' Radar -- Curis, Egalet, Esperion Therapeutics, and GlycoMimetics - PR Newswire (press release)|
www.prnewswire.com - November 2 at 7:36 PM
|Esperion Therapeutics, Inc. (ESPR) Scheduled to Post Earnings on Wednesday|
www.americanbankingnews.com - October 25 at 9:48 AM
|Esperion Therapeutics Becomes Oversold (ESPR)|
www.nasdaq.com - October 23 at 4:09 PM
|Esperion Therapeutics, Inc. (ESPR) Expected to Post Earnings of -$1.76 Per Share|
www.americanbankingnews.com - October 22 at 4:28 AM
|Esperion Therapeutics, Inc. (ESPR) Given Average Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - October 19 at 4:32 PM
|SPPI Breathes Easy On Trial Results, PTI Awaits Data In Q4, HAIR Keeps Receding|
www.rttnews.com - October 19 at 5:56 AM
|Esperion to Host Analyst and Investor Day Event on October 17|
finance.yahoo.com - October 10 at 4:09 PM
Esperion Therapeutics (NASDAQ:ESPR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Esperion Therapeutics (NASDAQ:ESPR) Income Statement, Balance Sheet and Cash Flow Statement
Esperion Therapeutics (NASDAQ ESPR) Stock Chart for Tuesday, January, 23, 2018